REG - Physiomics PLC - Director Dealing

PhysiomicsAnnouncement

08/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241108:nRSH4165La&default-theme=true

RNS Number : 4165L  Physiomics PLC  08 November 2024

8 November 2024

Physiomics plc

("Physiomics" or the "Company")

Director Dealing

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, announces that Dr Peter Sargent, Chief
Executive Officer and Director of the Company, has acquired, via market
purchases, 459,090 new ordinary shares of 0.4p in the Company ("Ordinary
Shares") at a price of 0.66p per Ordinary Share.

Accordingly, Dr Sargent's total holding in the Company will be 459,090
Ordinary Shares, representing approximately 0.2% of the Company's issued share
capital and 4,064,175 performance rights under the Company's existing share
option schemes (with various vesting targets and expiring on 5 February
2034).

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

PDMR Notification Form:

The notification below, which has been made in accordance with the
requirements of UK MAR, provides further details.

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Dr Peter Sargent
 2.  Reason for the Notification
 a)  Position/status                                              Chief Executive Officer and Director
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Physiomics plc
 b)  LEI                                                          213800A71DSZ6ABMTQ91
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Purchase of Ordinary Shares
     Identification code                                          GB00BDR6W943
 b)  Nature of the Transaction                                    Purchase of new Ordinary Shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  £0.0066   459,090
 d)  Aggregated information                                       N/A (Single transaction)

     Aggregated volume Price
 e)  Date of the transaction                                      7 November 2024
 f)  Place of the transaction                                     London Stock Exchange

d)

Aggregated information

Aggregated volume Price

N/A (Single transaction)

e)

Date of the transaction

7 November 2024

f)

Place of the transaction

London Stock Exchange

 

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBRBITMTAMBLI